News and Trends 8 Sep 2025
With Lykos CRL now public, FDA opens new era of accountability
As the release of a CRL declining Lykos’ therapy generates a strong reaction from MAPS, delve into what this new transparency could change.
About
After I graduated with a master’s degree in European Law from the
University of Tours, I decided to study journalism at the All Media
Journalism Institute of Lille. During this time, I discovered the healthcare
innovation ecosystem and enjoyed writing about it for Eurasanté, a French
healthcare cluster. I am interested in different subjects other than
healthcare and biotechnology: cinema, sports, photography… Journalism
had always been at the back of my mind, and I am delighted to write for
Labiotech as a junior reporter. When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.
Articles by Jules Adam
Interview 3 Sep 2025
Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand
As radiopharma is gaining momentum, read our interview with Dr. Delpassand, the CEO of RadioMedix’s, an established company of the field.
In Depth 1 Sep 2025
Blood Cancer Awareness Month: What biotech holds in store
As September marks the beginning of Blood Cancer Awareness Month, delve into what is being developed in the biotech pipelines.
More News! 27 Aug 2025
Zemcelpro, the first blood cord expansion therapy to reach the EU market
Find out about ExCellThera’s zemcelpro, the first blood cord expansion therapy to reach the European market, and only the second globally.
In Depth 22 Aug 2025
The Sanofi pipeline in 2025: Is the play-to-win strategy working?
Find out what Sanofi has been up to in 2025, especially as it just closed the Opella deal and is now expanding its pipeline.
In Depth 20 Aug 2025
From pasture to lab: The new biotech toolkit for cattle
Nature writes the best horror stories – In The New York Times’ recent piece, the return of the screwworm, a flesh‑eating parasite once eradicated from the U.S. Indeed, cattle ranchers are once again staring at wounds riddled with maggots. This insect, which devastated cattle in the 20th century, is making a comeback, spurring governments to […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 15 Aug 2025
How biotech is improving the life of your cat
About a week ago, on August 8th, fell International Cat Day. Even if you are a cat person like I am, you might have missed the event. Don’t worry, your feline probably didn’t know about it either. In this article, we will take a look at what biotech is doing in cat health. While the cat […]
Best in Biotech 24 Jul 2025
Which biotech companies are gaining traction in genetic diseases?
Discover twelve companies focused on genetic diseases that managed to close funding rounds in the last two years.
Best in Biotech 23 Jul 2025
Biotech stars of 2024, did they shine or fade in 2025?
Find out if the biotech companies Labiotech designated as the ones to keep an eye on in 2024 held up to our expectation in 2025.
In Depth 18 Jul 2025
Hyderabad’s Genome Valley, biopharma’s scale-up hub
Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.
Podcast 18 Jul 2025
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy
This week, I talked to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation.
News and Trends 10 Jul 2025
Radiopharma’s new wave: Nuclidium and Actithera raise the stakes
Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.
ADVERTISEMENT
